Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2011, vol. 20, nr 1, January-February, p. 93–101

Publication type: review article

Language: English

Breast Carcinoma – Diagnostics, Therapy and Resistance

Diagnostyka raka piersi – terapia i oporność na leczenie

Anna Kuźma-Richert1,, Jolanta Saczko2,, Julita Kulbacka2,

1 Internal Clinic, Regional Hospital, Lörrach, Germany

2 Department of Medical Biochemistry, Wroclaw Medical University, Poland

Abstract

Breast cancer is a pathologically and clinically heterogeneous disease with a variable prognosis. This type of cancer is the most common female cancer in Poland. According to data collected up to 2004, approximately 12,000 new breast cancer cases per year were diagnosed in women in Poland, and approximately 5000 patients died yearly of breast cancer. The authors present the histopathology, diagnostics, classification and general types of systemic therapy of breast cancer.

Streszczenie

Nowotwory piersi są patologicznie i klinicznie heterogenicznymi chorobami z różną prognozą. Do 2004 r. diagnozowano u kobiet w Polsce 12000 nowych przypadków zachorowań na raka piersi rocznie; z tego około 5000 pacjentek rocznie umiera z powodu raka gruczołu sutkowego. W pracy zaprezentowano histopatologię, diagnostykę, klasyfikację oraz różne typy standardowo stosowanej terapii wykorzystywanej w leczeniu nowotworów gruczołu piersiowego.

Key words

breast carcinoma, multidrug resistance

Słowa kluczowe

rak piersi, oporność wielolekowa

References (36)

  1. Krzakowski M: Rak piersi – charakterystyka problemu zdrowotnego w Polsce. Stowarzyszenie Kobiet z Problemem Onkologicznym, Biuletyn nr 54, 2008.
  2. Pfeifer B, Preiss J, Unger C: Onkologie integrativ. Urban&Fischer, 2006.
  3. Chodosh LA: The Reciprocal Dance between Cancer and Development. NEJM 2002, 347, 134–136.
  4. Kreipe HM: Mehr als Staging, Typing und Grading – die Rolle der Mammapathologie heute. Onkologie Heute Nr.1/Januar 2010, 14–19.
  5. Petrasch S, Ehninger G: Update Haematologie/Onkologie. Mammakarzinom. Lukon Verlagsgesellschaft mbH Muenchen 2007.
  6. Singletary SE, Connolly JL: Breast Cancer Staging: Working with the Sixth Edition of the AJJC Cancer Staging Manual. CA Cancer J Clin 2006, 56, 37–47.
  7. Schummer M, Green A, Beatty JD, Karlan BY, Karlan S, Gross J, Thomton S, McIntosh M, Urban N: Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection. PLoS One 2010 Feb. 9, 5(2), e9122.
  8. Hobday TJ, Perez EA: Molecularly Targeted Therapies for Breast Cancer. Cancer Control 2005, 12(2), 73–81.
  9. Schlotter CM, Vogt U, Allgayer H, Brandt B: Molecular Therapies for Breast Cancer. Breast Cancer Res 2008, 10, 211.
  10. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A: Recent Advances in Systemic Therapy: New Diagnostics and Biological Predictors of Outcome in Early Breast Cancer. Breast Cancer Res. 2009, 11(2), 205, 1–11.
  11. Pestalozzi B, Castiglione M: Primary Breast Cancer: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-up. Ann Oncol 2008, Suppl. 2, 7–10.
  12. Singh V, Saunders C, Wylie L, Bourke A: New diagnostic techniques for breast cancer Detection. Future Oncol 2008, 4(4), 501–503.
  13. Sedlmayer F, Reitsamer R, Fastner G, Menzel C: Intraoperative Radiotherapie mit Elektronen (IOERT) als antizipiertes Boostverfahren beim konservativ operierten Mammakarzinom. Onkologie heute Nr. 1/Januar 2010, 30–36.
  14. Rottenberg S, Nygren AOH, Pajic M, van Leeuwen FWB, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen Olaf, Schouten JP, Jonkers J, Borst P: Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Edited by Inder M. Verma, The Salk Institute for Biological Studies, La Jolla, CA, and approved June 1, 2007. PNAS.
  15. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008, 34(4), 378–390.
  16. Wang W, El-Deiry WS: Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008, 20(1), 90–96.
  17. van Leeuwen FWB, Buckle T, Kersbergen A, Rottenberg S, Gilhuijs KGA: Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensivity. Eur J Nucl Med Mol Imaging 2009, 36, 406–412.
  18. Strother RM, Jones D, Li L, Younger A, Einhorn LH, Williams S, Sweeney CJ: Effect of the C2435T genetic polymorphism in MDR1 on etoposide pharmacokinetics. J Clin Oncol 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S, 2008, 2500.
  19. Liu R, Page C, Beidler DR, Wicha MS, Nunez G: Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 1999 Dec, 155(6), 1861–1867.
  20. Lehnert M: Chemotherapy resistance in breast cancer. Anticancer Res 1998 May-Jun, 18(3C), 2225–2226.
  21. Venkat C: Multi Drug Resistance to Chemotherapy. CLL Topics 2003.
  22. Rajagopal A, Sanford MS: Subcellular Localization and Activity of Multidurg Resistance Proteins. Mol Biol Cell 2003, 14(8), 3389–3399.
  23. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EH, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxity. Circulation 2005, 112(24), 3754–3762.
  24. Ecker GF, Csaszar E, Kopp S, Plagens B, Holzer W, Ernst W, Chiba P: Identification of Ligand-Binding Regions of P-Glycoprotein by Activated-Pharmacophore Photoaffinity Labelling and Matrix-Assisted Laser Desorption/ Ionisation-Time-of-Flight Mass Spectometry. Mol Pharmacol 2002, 61, 637–648.
  25. Misra S, Ghatak S, Zoltan-Jones A, Toole BP: Regulation of Multidrug Resistance in Cancer Cells by Hyaluronan. J Biol Chem 2003, 278(28), 25285–25288.
  26. Capella MAM, Capella LS: A Light in Multidrug Resistance: Photodynamic Treatment of Multidrug-Resistance Tumors. J Biomed Sci 2003, 10(4), 361–366.
  27. Zaremba M: Lekooporność w nowotworach wieku dziecięcego. Część I – białka związane z lekoopornością. Onkol Pol 2005, 8(2), 57–61.
  28. Kataja V, Castiglione M: Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow up. Ann Oncol 2009, 20(4); Pp.iv10–iv14.
  29. Kaufmann M, von Minckwitz G, Costa SD: Hochdosis-Chemotherapie beim Mammakarzinom: Gehen wir den richtigen Weg? Dtsch Aerztebl 1997; 94(43): A-2835/B-2411/C-2257 11, 2002, Vol. 347, 134–136, Number 2.
  30. Lueftner D, Jehn C: Bericht vom San Antonio Breast Cancer Symposium. Onkologie heute Nr. 1/Januar 2010, 54–58.
  31. Leinmueller R: Mammographie Screening. Der Streit um den Nutzen geht in die naechste Runde. Dtsch Aerztebl 2010, 107, 15.
  32. Ganz PA: Survivorship: Adult Cancer Survivors. Prim Care 2009, 36(4), 721–741.
  33. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Boehm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K, ACRIN 6666 Investigators: Combined screening with ultrasound and mammography via mammography alone in women at elevated risk of breast cancer. JAMA 2008, May 14, 299(18), 2151–2163.
  34. Ruckhaeberle E, Rody A: Zielgerichte Therapie beim Mammakarzinom. Onkologie Nr. 5/September 2009, 32–39.
  35. Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, Buscombe J, Strauss HW, Paganelli W: Radioguided Sentinel Lymph Node Biopsy in Breast Cancer Surgery. J Nucl Med 2001, 42, 1198–1215.
  36. Deantonio L, Gambaro G, Masini L, Tunesi S, Magnani C, Krengli M: Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol 2010, 5, 112.
© Wroclaw Medical University